Mayer Fishman

9.5k citations

147 papers · 6.3k indexed · 3 hit papers · h-index 37

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
Immunology top 1%
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 82
- Cancer Immunotherapy and Biomarkers 51
Pulmonary and Respiratory Medicine 81
- Renal cell carcinoma treatment 59
- Prostate Cancer Treatment and Research 12

Co-authors: Dmitry I. Gabrilovich Scott Antonia Yulia Nefedova Simon Sherman Richard M. Lush Paul B. Jacobsen Xingyu Wang Amer A. Beg
Journals: Journal of Clinical Oncology (41 papers)Clinical Cancer Research (9 papers)Cancer (6 papers)Clinical Genitourinary Cancer (5 papers)Cancer Research (5 papers)
Partner nations: United States Germany France

In The Last Decade

Mayer Fishman

145 papers receiving 6.2k citations

Hit Papers

align trajectories log scale

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial 2018 · 274 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 The Lancet Oncology
2017 JAMA Oncology
2010 Nature Medicine

Peers

Countries citing papers authored by Mayer Fishman

Since Specialization

Citations

This map shows the geographic impact of Mayer Fishman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mayer Fishman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mayer Fishman more than expected).

Fields of papers citing papers by Mayer Fishman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mayer Fishman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mayer Fishman. The network helps show where Mayer Fishman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mayer Fishman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mayer Fishman Line = papers co-authored together Mayer Fishman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study CardioVascular and Interventional Radiology ·Tatsuya Noda, Rahul Mhaskar, Rohit Jain, Jingsong Zhang, Jessica M. Frakes, Sarah E. Hoffe, Ghassan El‐Haddad, Nainesh Parikh, Liu Zhi-Hang, Mayer Fishman, Junsung Choi, Béla Kis	2021	5
2	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma Clinical Cancer Research ·Jean-François Martini, Elizabeth R. Plimack, Toni K. Choueiri, David F. McDermott, Igor Puzanov, Mayer Fishman, Daniel C. Cho, Ulka N. Vaishampayan, A. N. Green, Kathrine C. Fernandez, Jamal Tarazi, Saby George, Michael B. Atkins	2020	16
3	Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer Cancer ·Tanya B. Dorff, Jeff Longmate, Sumanta K. Pal, Walter M. Stadler, Mayer Fishman, Ulka N. Vaishampayan, Z. A. Zhu, G Czarnowski, James Hu, David I. Quinn, Primo N. Lara	2017	36
4	Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic Lesions Cancer Research ·Jan Poleszczuk, Kimberly A. Luddy, Gerald Etapelongg, Mark Robertson‐Tessi, Eduardo G. Moros, Mayer Fishman, Julie Y. Djeu, Steven E. Finkelstein, Heiko Enderling	2016	92
5	A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting PLoS ONE ·Mayer Fishman, I.C. Krap, William J. Fulp, Pamela K. Foreman	2015	25
6	Effects of Notch Signaling on Regulation of Myeloid Cell Differentiation in Cancer Cancer Research ·Pingyan Cheng, Vinit Kumar, Hao Liu, Je-In Youn, Mayer Fishman, Simon Sherman, Dmitry I. Gabrilovich	2013	79
7	Axitinib for the Treatment of Metastatic Renal Cell Carcinoma American Journal of Clinical Oncology ·James Larkin, Mayer Fishman, Laura S. Wood, Sylvie Négrier, G. Reis Mitermayer, J. B. B., I. Kostyukov, Eric Jonasch, Lori B. Andrews, Michael Staehler	2013	17
8	Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma European Journal of Cancer ·Mayer Fishman, S. Srinivas, Ralph J. Hauke, R. J. Amato, Jessica Foss, Monette Cotreau, Andrew Strahs, William J. Slichenmyer, Pankaj Bhargava, Fairooz F. Kabbinavar	2013	25
9	Clinical opportunities in combining immunotherapy with radiation therapy SHILAP Revista de lepidopterología ·Steven E. Finkelstein, Mayer Fishman	2012	33
10	A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer Clinical Cancer Research ·David S. Hong, Razelle Kurzrock, Yun Oh, Jennifer J. Wheler, Aung Naing, Les Brail, Sophie Callies, Valérie André, Sunil Kadam, Aejaz Nasir, Timothy R. Holzer, Funda Meric‐Bernstam, Mayer Fishman, George R. Simon	2011	113
11	Sipuleucel-T: Prototype for Development of Anti-tumor Vaccines Current Oncology Reports ·Estrella M. Carballido, Mayer Fishman	2011	23
12	Progress and contrasts of the development of tivozanib for therapy of kidney cancer Expert Opinion on Pharmacotherapy ·Shilpa Gupta, Mayer Fishman	2011	4
13	Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer Clinical Cancer Research ·Srinivas Nagaraj, Je-In Youn, Hannah Weber, Cristina Iclozan, Lily Lu, Matthew J. Cotter, Colin J. Meyer, Carlos Becerra, Mayer Fishman, Scott Antonia, Michael B. Sporn, Karen T. Liby, Bhupendra Rawal, Ji‐Hyun Lee, Dmitry I. Gabrilovich	2010	225
14	A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer Expert Opinion on Biological Therapy ·Mayer Fishman	2009	26
15	Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel Clinical Cancer Research ·Gerald J. Fetterly, Thaddeus H. Grasela, Jeffrey W. Sherman, Francisco Aguirre, Amy Grahn, D Lecomte, Jill Fiedler‐Kelly, Nevena Damjanov, Mayer Fishman, Michael P. Kane, Eric H. Rubin, Antoinette R. Tan	2008	56
16	Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma Journal of Immunotherapy ·Mayer Fishman, Terri Hunter, Hatem Soliman, Patricia Thompson, Mary Dunn, A. V. Gritsay, Gareth W. Grifith, David Noyes, J. J. Mahany, Ji‐Hyun Lee, Alan Cantor, Chair Shun-ichi Chitose, John D. Seigne, Julio M. Pow‐Sang, William E. Janssen, Scott Antonia	2008	52
17	Mechanism of All- Trans Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells Cancer Research ·Yulia Nefedova, Mayer Fishman, Simon Sherman, Xingyu Wang, Amer A. Beg, Dmitry I. Gabrilovich	2007	347
18	Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer Quality of Life Research ·Patrick W. Sullivan, Parvez Mulani, Mayer Fishman, Darryl J. Sleep	2007	62
19	Ultrastructural Dynamics of Mitochondrial Morphology in Varying Functional Forms of Human Adrenal Cortical Adenoma Hormone and Metabolic Research ·Stefan R. Bornstein, Julia Brown, A. Carballeira, Maria Rosaria Villa, Werner A. Scherbaum, Mayer Fishman	1996	14
20	End-to-end distance distributions of flexible molecules: frequency-domain fluorescence energy transfer measurements and rotational isomeric state model calculations Macromolecules ·Joseph R. Lakowicz, Wiesław Wiczk, Ignacy Gryczyński, Mayer Fishman, Michael L. Johnson	1993	17

About Mayer Fishman

Mayer Fishman is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Nephrology, having authored 147 papers that have together received 6.3k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (59 papers), Cancer Immunotherapy and Biomarkers (51 papers), Renal and related cancers (23 papers), Cancer Genomics and Diagnostics (21 papers), Immunotherapy and Immune Responses (19 papers), Bladder and Urothelial Cancer Treatments (19 papers), Prostate Cancer Treatment and Research (12 papers) and Economic and Financial Impacts of Cancer (10 papers). The work is most often cited by research in Oncology (3.1k citations), Immunology (2.2k citations), Cancer Research (924 citations), Pulmonary and Respiratory Medicine (1.8k citations) and Molecular Biology (1.9k citations). Mayer Fishman has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Dmitry I. Gabrilovich, Scott Antonia, Yulia Nefedova, Simon Sherman, Richard M. Lush, Paul B. Jacobsen, Xingyu Wang, Amer A. Beg, Mary Dunn and Heather Jim. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer, Clinical Genitourinary Cancer and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact